ADC Therapeutics SA (ADCT) Misses Q4 EPS by 51c

ADC Therapeutics SA (NYSE: ADCT) reported Q4 EPS of ($0.97), $0.51 worse than the analyst estimate of ($0.46). Revenue for the quarter came in at $16.79 million versus the consensus estimate of $15.32 million.

For earnings history and earnings-related data on ADC Therapeutics SA (ADCT) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Outlook Therapeutics (OTLK) Misses Q3 EPS by 9c
• Silexion Therapeutics (SLXN) Tops Q2 EPS by 793c